Introduction
Digoxin is the most commonly prescribed cardiac glycoside in the United Kingdom. It is used to slow the heart rate in supraventricular arrhythmias and to assist in the control of cardiac failure: as these are common conditions it is very widely used. It has been estimated that digoxin is currently being taken by over 250,000 patients in this country.
The ratio between effective and toxic doses of digoxin is often low, particularly in patients with myocardial disease. The response of individual patients to digitalis is unpredictable and dose has to be carefully matched to response. Toxicity is associated with an appreciable mortality and morbidity (Beller et al., 1971) , but may easily be missed (Lely and van Enter, 1972; Chamberlain, 1972) .
In these circumstances it is clearly important that preparations of digoxin should be of consistent potency. It was to achieve this that the purified glycosides digoxin and digitoxin largely replaced the galenical preparations. However, since the introduction of assays for the measurement of plasma digoxin concentrations it has become clear that digoxin preparations in use throughout the world vary widely in potency. It is now known that tablets of digoxin may contain the correct dose but have only a fraction of this dose absorbed by the patient (low 'biological availability'). The average amount absorbed varies from brand to brand and with some brands from batch to batch. (Wayne, 1933 (Chamberlain et al., 1970) (Fig. 1) (Shaw, Howard and Hamer, 1973) . Figure 2 shows the plasma digoxin levels recorded in our department in patients using Lanoxin manufactured during these three periods of time. From 1970 -May 1972 Journal, 1972; Lancet, 1972 (Fig. 3) . In some individual cases the older Lanoxin had produced higher levels than other brands (Shaw, Howard and Hamer, 1972) . The mean levels found with the group of 'other brands' is influenced both by the bio-availability of individual brands and by the frequency with which each brand was used. Most of the commonly used brands resembled the older Lanoxin. The differences in older and newer Lanoxin had been paralleled by changes in the in vitro dissolution rate of the tablets (Fig. 4) . The dissolution rates of most of the other brands available in Britain approximate that of older Lanoxin but some dissolve as rapidly as the newer Lanoxin Cowan, 1972, 1973; Shaw 1973 ). This strongly suggested that the other brands were far from equivalent in efficacy. This non-equivalence has been confirmed by studies on individual brands chosen to represent a range of dissolution rates (Shaw et al., 1973b) and is illus- In addition some brands show startling variation in dissolution rate from batch to batch (Fig. 5) . Enquiries have shown that other companies have modified their production method in recent years.
The variation between brands appears to be due to the effect that different production methods have on the digoxin particle size (Shaw et al., 1973a) . (Fig. 6 ). There safe fixed ratio of dose equivalence for di brands. 
